|
A 1991 market analysis indicated that pharmaceutical companies would require services for measuring, analyzing and evaluating health care. Due to an ever increasing aging population and pressures on industry to keep health costs down, the buyers and sellers of health care services are becoming more and more concerned with measuring the overall effectiveness of therapeutic and prevention programs. It is projected that pharmaceutical companies and related health care industries will need data and information to market their products competitively and to defend higher prices by evaluating expanded patient outcomes. With over 10 years experience in the field of quality of life and human health economics, PHASE V is well-positioned to design and carry-out a health economics evaluation program for a new pharmaceutical agents.
|
